Enhancing Endometrial Cancer Management: Highlights of Molecular Insights, Treatment Approaches, and Toxicity Management

This activity was originally broadcast as part of the 2024 Directions in Oncology Pharmacy® conference.

The patient cases discussion portion of the program also includes discussion on immune-related adverse effects.

Program Description

Tailoring treatment based on individual patient characteristics, such as molecular biomarkers or genetic mutations, is becoming increasingly important in cancer care. This remains true for patients living with endometrial cancer, considering the significance of molecular classification and genetic components such as Lynch syndrome in predicting disease and treatment response. Oncology pharmacists must understand the significance of molecular testing in facilitating the selection of targeted therapies that specifically address those alterations, increasing the likelihood of effectiveness and minimizing adverse effects. Recent clinical evidence has proven the utility of immune checkpoint inhibitors (ICIs) in combination with chemotherapy as a frontline option recommended for the treatment of recurrent endometrial cancer. In this session, participants will gain insights into the latest advancements in molecular testing and how these tests can inform the timing and selection of appropriate therapies. Through the use of patient cases, faculty presenters will illustrate the clinical implications of molecular testing and the practical aspects of ICI management to personalize treatment regimens for patients with endometrial cancer.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: November 25, 2024
Expiration date: November 25, 2025

Time to complete activity: 1.0 hour

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply molecular testing insights to patient evaluations to improve the timing and choice of therapies for those diagnosed with endometrial cancer
• Ensure appropriate use of checkpoint inhibitor-based treatment strategies in advanced or recurrent endometrial cancer based on patient and disease-specific characteristics
• Construct strategies to manage and mitigate toxicities of systemic endometrial cancer therapies, including dose adjustments, supportive care, and patient education

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-333-H01-P. The activity is available for CE credit through November 25, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Megan May, PharmD, BCOP, FHOPA, FAPO, has the following financial relationships with commercial interests to disclose:
Consultant: Amgen Inc, Lilly

Speakers Bureau: Amgen Inc, AstraZeneca

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Daphne Davis, PharmD, BCOP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Medical reviewer Erin Zacholski, PharmD, BCOP, has the following relevant financial relationship with a commercial interest to disclose:
Consultant: Verastem, Inc

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms

PDF of Presentation Slides